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Abstract
Background: In Creutzfeldt-Jakob disease (CJD) and other related transmissible spongiform
encephalopathies it is critical to understand the various pathways by which the infectious agent
spreads to different organs.
Methods: We injected a CJD agent into mice, either intracerebrally (ic) or intraperitoneally (ip)
and monitored the progressive appearance of abnormal PrP in peripheral tissues over time.
Results: Abnormal PrP was detected in lymphoreticular tissues of the gastrointestinal tract as
early as 28 to 32 days after infection by both routes. This change persisted until the terminal stages
of disease. In contrast, abnormal PrP was not detected in brain or spinal cord until 80 to 120 days
after ic inoculation, or until 170 days after ip inoculation.
Conclusions: Brain lacks significant lymphatic drainage, and has little infectivity before 40 days,
even after ic inoculation. Thus the infectious inoculum must spread to the gut by a vascular route,
a direction opposite to that generally assumed. This interpretation is consistent with previous
studies demonstrating white blood cell infectivity as well as perivascular PrP accumulations in CJD.
Notably, enteric infection at early as well as later stages of disease, and regardless of the route of
agent entry, implicates potential environmental spread by fecal matter.
Background
Increasing evidence suggests that bovine spongiform en-
cephalopathy (BSE) agents spread more rapidly and uni-
versally via contaminated food than was previously
assumed. Experimentally, the oral route of infection is
very inefficient with most strains of scrapie and Creut-
zfeldt-Jakob disease (CJD). Nevertheless, the infectious
agent has been recovered from the distal ileum during
the late stages of BSE (reviewed in [1]). This enteric re-
gion is replete with lymphoid Peyer's patches that are
typically targeted by many penetrating viruses. Addi-
tional studies in non-human primates have shown that
an abnormal form of host prion protein (PrP) accumu-
lates in Peyer's Patches at ≥  5 months after oral infection,
a time when animals already had neurologic changes [2].
Other immunocytochemical studies have suggested that
the infectious agent spreads through the body only after
first targeting the gastrointestinal tract [3]. Since neuro-
nal ganglia and fibers of the gut wall were interpreted to
contain abnormal PrP histologically, neuronal fibers
have often been assumed to be conduits by which the
agent spreads from the periphery into the brain [4].
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However, because Peyer's patches show similar changes
after intraperitoneal (ip) inoculation with CJD agents
[5,6], we questioned the validity of unidirectional flow of
agent away from the gut, as well as whether infectious ex-
tension occurs exclusively via neurons.
Methods
We inoculated mice either ip or ic with 10 µl of isotonic
saline containing 1% (v/v) of a mouse brain homogenate
with the FU (or Fukuoka 2) strain of CJD, and the pas-
saged brain contained ~109 infectious units/gm wet
weight. Control mice received equivalent injections of
homogenate from a normal mouse brain. At each time
point indicated in Table 1, four mice were sacrificed and
evaluated for PrP pathology. Ileal Peyer's patches, intra-
peritoneal lymph nodes, spleen, bladder, lung, kidney,
pancreas, spinal cord and brain were fixed in either 10%
formalin (2 each) or perfused (2 each) with buffered 4%
paraformaldeyde before paraffin embedding. To confirm
infectivity of the inoculum, four mice in each inoculated
group (ip and ic) were kept until they displayed terminal
signs and spongiform brain pathology and gliosis. Re-
sults with the ic route were the same as previously de-
tailed for additional molecular markers [7]. The small
size of individual gut associated lymphatic tissues
(GALT) and the microscopic nature of neuronal plexi
precluded analysis of PrP by Western blotting. Thus, in
situ immunohistology was used to evaluate abnormal
PrP in the gut as described [1]. Numerous larger tissue
samples in our laboratory have been evaluated by both
methods, and all cases of positive PrP histopathology
have shown positive PrP-res by Western blotting. All tis-
sues were treated and evaluated with equivalent speci-
men from uninfected mice.
Results
Abnormal PrP accumulation is a sign of agent invasion.
Because ileal Peyer's patches were insufficient for West-
ern blotting analysis of PrP change, and could not be
cleanly dissected, we used in situ methods that abolish
virtually all background PrP of normal animals in the
majority of brain nuclei as previously depicted [1,7].
Larger PrP positive specimens invariably yielded posi-
tive PrP-res by Western blotting. However, some large
neurons in the brainstem as well as islet cells of the pan-
creas typically maintained prominent PrP staining even
after heat and limited proteolytic treatment. This inabil-
ity to distinguish abnormal PrP in these few instances
may not be resolvable by Western blotting since PrP
from normal islet cells can also be maintained after pro-
teolysis in electrophoretic analyses [8]. Similarly, the
large neurons of gut showed equivocal PrP stain differ-
ences between normal inoculated and CJD infected mice
beginning at day 2 after ip or ic injection. Therefore the
PrP stain was not sufficiently specific to conclude the in-
fectious agent associated with these enteric neurons. In
particular, the assumption of infectivity in these neurons
at early stages of infection is made even more tenuous by
the finding that significant agent replication in the brain
occurs only 40 days after ic inoculation [9].
In all the other tissues, the differences in PrP between
uninfected control and CJD mice were obvious. The time
course of infection in brain and gastrointestinal organs is
shown in Table 1. Within each group (n = 4), all mice
consistently exhibited similar negative or positive chang-
es in PrP. For comparison, the relevant data from se-
quential ip inoculation experiments are summarized in
Table 1 (as indicated by asterisks). Between 28 and 32
days after infection, distinct changes in PrP were detect-
ed in all abdominal lymphoid tissues examined, includ-
Table 1: Abnormal accumulation of PrP at various post inoculation stages.
Abnormal PrP CJD:days pi NORMAL:days pi
TISSUE (route) 2 4 14 28*–32 42 70* 90*–120 >170* 2 32 240
central
B r a i n  ( i c ) --- - -- + n a ---
Spinal cord (ic) - - - - - - + na - - -
Brain (ip) - - - - - - - + - - -
S p i n a l  c o r d  ( i p ) --- - -- - + ---
peripheral
Peyer's Patch (ic) - - - + + + + na - - -
L y m p h  n o d e  ( i c ) --- + + + + n a ---
S p l e e n  ( i c ) --- + + + + n a ---
Lymph nodes (ip) - - - + nd + + + - nd -
S p l e e n  ( i p ) --- + + + + + ---BMC Infectious Diseases 2001, 1:20 http://www.biomedcentral.com/1471-2334/1/20
ing Peyer's patches, central and peripheral mesenteric
lymph nodes, and the spleen. In Peyer's patches, PrP
changes were found on follicular dendritic cells (Figure
1), as well as in myeloid cells peripheral to germinal cent-
ers. This pathology of PrP accumulation on follicular
dendritic cells was similar to that demonstrated in spleen
by confocal microscopy, as described previously [8].
Control mice showed no such changes (Figure 1). At 28–
32 days, equivalent accumulations of abnormal PrP were
also detected in abdominal lymphoid tissues, as repre-
sented in Table 1 by spleen and lymph nodes. These
changes were comparable at this time, regardless of
whether agent was inoculated peripherally (ip) or cen-
trally (ic). Kidney and lung were negative for abnormal
PrP. However, the bladder wall showed abnormal PrP in
lymphoid regions, although epithelial cells were not pos-
itive.
In contrast to gut and abdominal lymphoid tissues, no
abnormalities in PrP were detected in brain or spinal
cord until much later after infection. Abundant abnor-
mal PrP became apparent in both the spinal cord and
brain only between 90 to 120 days after ic inoculation
and >170 days after ip inoculation.. Cerebral sections
showed focal deposits of pathologic PrP in regions with
spongiform changes at these more terminal stages as
shown in Figure 1. Similarly, studies have shown that PrP
change in the cerebrum switches from marginal to clear
cut between 70–80 days, and other studies have shown
significant increases in infectivity beginning at 60 days
after ic inoculation [7,9].
Discussion
These experiments demonstrate abnormalities in PrP
develop in the gut occur during early subclinical phases
of infection, a time when PrP and spongiform change is
Figure 1
Representative sections of gut, spleen, and brain stained for abnormal PrP at sequential times after ic inoculation. (A – C) No
pathologic PrP is observed four days after inoculation. (D – F) Only lymphoid tissues are positive 32 days after inoculation. (G
– I) Clinically ill mice show abnormal PrP accumulation in brain as well as in lymphoid tissues 120 days after inoculation. The
arrow in H shows a positive cell outside the germinal center that is morphologically consistent with a macrophage or dendritic
cell. Methods for inoculation, fixation and detection of PrP detection have been described previously [1].BMC Infectious Diseases 2001, 1:20 http://www.biomedcentral.com/1471-2334/1/20
not yet detectable in the central nervous system. Al-
though infectious agent can sometimes elicit little patho-
logic PrP, and can be separated from most PrP during
brain fractionation [10], abnormal PrP is produced only
after or during exposure to the infectious agent. It is
therefore remarkable that mice challenged with CJD via
ic or ip routes exhibited the same early temporal pattern
of PrP accumulation in the gastrointestinal tract. The
presence of PrP-positive cells in the gut therefore does
not implicate an oral route of infection, and furthermore
indicates a common route of spread that does not involve
neurons.
The gastrointestinal tract would appear to be the natural
route of infection with CJD in response to oral exposure
to the infectious agent. In orally delivered scrapie, there
was immediate uptake of infectivity and agent replica-
tion in Peyer's patches as assayed by end-point dilution.
This enteric increase in infectivity preceded infection in
the spleen and spinal cord [3] and the favored concept
has been that the agent spreads by lymphatics from the
gut to the spleen, and into the spinal cord via the enteric
and splenic sympathetic neurons. After ip scrapie, neu-
roinvasion may also be initiated through specific sites in
the medulla, essentially excluding the lymphoreticular
system as an important conduit for agent spread [4]. In
the present experiments where agent was delivered in-
tracerebrally, the lymphatic channels are probably irrel-
evant because the brain does not have significant
lymphatic drainage. However, inoculation trauma to the
brain allows most agent to be rapidly released through
disrupted traumatized vessels or cleared via active cellu-
lar processes such as phagocytosis [9]. Many studies with
visible tracers have shown inoculated materials travel
out via vascular channels, and similarly CJD is detected
in blood just after inoculation [11].
The present studies therefore indicate these agents
spread via blood, with neural routes playing a secondary
role. Original studies in CJD revealed a hematogenous
route for agent spread after ic inoculation, and agent
could also be detected in white blood cells later in disease
[11,12]. For example, white blood cells from guinea pigs
infected with CJD repeatedly caused disease in recipi-
ents, including the initial three weeks after ic inoculation
[11]. This early appearance of blood infectivity coincided
with the loss and/or clearance of most infectivity away
from the brain [9]. At later stages of the disease, when
the CJD agent had replicated substantially in brain, even
higher levels of agent reappeared in the blood. In con-
trast, blood is claimed not to contain infectivity in a
scrapie mouse model [13]. However mice do not survive
inoculation with 20% white blood cell homogenates as
was used to detect infectivity in guinea pigs. Further-
more others have found white blood infectivity in ham-
sters, mice and humans [14] and Houston and co-
workers recently demonstrated that BSE could be trans-
mitted by transfusion from a sheep that had been orally
infected with BSE [5]. The wide dissemination of agent to
many distant tissues and the perivascular PrP pathology
in the brain after ip infection also support a hematoge-
nous route of agent spread [6,8]. There is also a danger
of over interpreting high levels of PrP in some neurons
where the histologic picture may not be specific for infec-
tion, as in the myenteric plexus neurons noted here.
Additional arguments pointing to blood as the source of
early infectivity, perhaps even more than neurons, were
derived from direct analyses of dental tissue. After ip
challenge with scrapie, infectivity was higher in gingival
tissues than in dental pulp, and trigeminal ganglia lacked
detectable infectivity until >50 days after inoculation
[15]. Our current study adds further evidence suggesting
that blood itself is the carrier of the infectious agent, as
spinal cord showed no abnormal PrP after ic inoculation
at times when clear signs of agent invasion were present
in GALT. In the case of BSE, and potentially with vCJD
in humans, it has now become accepted that transfused
blood could be infectious [16,17]. The current studies
reemphasize the probability of white blood cell infection
in virtually all transmissible spongiform encephalopa-
thies of animals and man.
While several types of white blood cells may effectively
spread agent via blood to many organs including brain,
macrophages and other myeloid cells like dendritic cells
appear to be involved. Spleen myeloid cells 28–32 days
after infection showed significant infectivity after ex-
tended culture [8]. In accord with this, we detected PrP-
positive cells with a myeloid migratory morphology in
enteric Peyer's patches here at the same early time.
Moreover, in chronic studies of transgenic mice with spe-
cific immune cell deficiencies, similar migratory cells
outside of germinal centers and around small vessels
contained abnormal PrP in the submucosal interstitium
of the gut. Superficial epithelial and M cells were labeled
less frequently [6]. This data further supports the blood
borne route of agent toward the gut. It is important to
recognize this direction of agent invasion, because it is
often assumed that early infection of gut, as in a diagnos-
tic setting, is acquired only through feeding.
The widespread infection of gastrointestinal lymphore-
ticular tissues is important epidemiologically because it
suggests there can be shedding of agent into the gut lu-
men during all stages of infection. This mechanism may
be particularly important if common gastrointestinal in-
fections and chemical irritations lead to superficial epi-
thelial and submucosal shedding. Similarly, small
amounts of agent might be shed through the urine underBMC Infectious Diseases 2001, 1:20 http://www.biomedcentral.com/1471-2334/1/20
some circumstances. These findings raise the concern
that if the agent is repeatedly shed into the environment,
it may be extremely difficult to completely eradicate BSE
in endemic areas where thousands of cows have been in-
fected. The presence of any of these agents (BSE, scrapie,
CJD) in excreted materials, including cow manure used
as fertilizer could be a source for continuing human and
animal spread.
Conclusions
In these studies, we provide evidence that blood can car-
ry the CJD agent toward the gastrointestinal tract in a di-
rection opposite to that commonly assumed. Peripheral
PrP pathology can be detected months before significant
agent replication in the brain. The fact that the agent can
spread through blood into excretory organs such as gut
implicates potential shedding of agent into the environ-
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